N-[4-硝基-3-(三氟甲基)苯基]-(2S)-3-[4-(乙酰基氨基)苯氧基]-2-羟基-2-甲基丙酰胺

 主页 / 产品目录 / API / N-[4-硝基-3-(三氟甲基)苯基]-(2S)-3-[4-(乙酰基氨基)苯氧基]-2-羟基-2-甲基丙酰胺
N-[4-硝基-3-(三氟甲基)苯基]-(2S)-3-[4-(乙酰基氨基)苯氧基]-2-羟基-2-甲基丙酰胺

N-[4-硝基-3-(三氟甲基)苯基]-(2S)-3-[4-(乙酰基氨基)苯氧基]-2-羟基-2-甲基丙酰胺

编号ABP000375 化学名称Andarine/ CAS401900-40-1 MDL: MFCD09027386 分子式C19H18F3N3O6 分子量441.36 纯度 >99%

化学名称 : N-[4-硝基-3-(三氟甲基)苯基]-(2S)-3-[4-(乙酰基氨基)苯氧基]-2-羟基-2-甲基丙酰胺

CAS : 401900-40-1

英文名称: Andarine/

英文同义词: OSTARINE

溶解度:Unknown

储存条件:Storage at -20C 2 years

生物活性

Andarine (S-4) is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy,[1] using the non-steroidal androgen antagonist bicalutamide as a lead compound.[2] Andarine is an orally active partial agonist for androgen receptors. It is less potent in both anabolic and androgenic effects than other SARMs. In an animal model of benign prostatic hypertrophy, andarine was shown to reduce prostate weight with similar efficacy to finasteride, but without producing any reduction in muscle mass or anti-androgenic side effects.[3] This suggests that it is able to competitively block binding of dihydrotestosterone to its receptor targets in the prostate gland, but its partial agonist effects at androgen receptors prevent the side effects associated with the anti-androgenic drugs traditionally used for treatment of BPH.[4] Clinical development of Andarine has been abandoned, given in humans it results in a series specific toxic metabolite

参考文献

1. Zilbermint MF,et al. Future Oncol. 2009 Oct;5(8):1211-20. http://www.ncbi.nlm.nih.gov/pubmed/19852734?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1 2. Madeddu C,et al. Curr Opin Support Palliat Care. 2009 Dec;3(4):258-62. http://www.ncbi.nlm.nih.gov/pubmed/19667995?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=2 3.http://www.gtxinc.com/Pipeline/OstarineMK2866.aspx?Sid=4

询价